Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

18.44
Delayed Data
As of 4:00pm ET
 +0.96 / +5.49%
Today’s Change
8.00
Today|||52-Week Range
41.97
-52.20%
Year-to-Date
Sarepta Therapeutics (SRPT) Stock Jumps on Possibility of New Drug Approval
1:46pm / TheStreet.com - Paid Partner Content
3 Risky Biotechs With FDA Decisions On Deck -- Are They Buys?
May 12 / MotleyFool.com - Paid Partner Content
Forget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy
May 19 / MotleyFool.com - Paid Partner Content
What's Sarepta Therapeutics Inc.'s Next Move?
May 10 / MotleyFool.com - Paid Partner Content
How George Soros Invests in Biotech
May 18 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close17.48
Today’s open18.29
Day’s range17.57 - 18.97
Volume5,543,488
Average volume (3 months)4,914,042
Market cap$800.1M
Dividend yield--
Data as of 4:00pm ET, 05/24/2016

Growth & Valuation

Earnings growth (last year)-53.39%
Earnings growth (this year)+12.91%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)-87.16%
P/E ratioNM
Price/Sales1,302.11
Price/Book4.19

Competitors

 Today’s
change
Today’s
% change
RGENRepligen Corp+0.62+2.64%
MGNXMacroGenics Inc+0.81+3.58%
LCILannett Company Inc+0.78+3.49%
CPXXCelator Pharmaceutic...-0.71-3.98%
Data as of 4:02pm ET, 05/24/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.20
Annual revenue (last year)$1.3M
Annual profit (last year)-$220.0M
Net profit margin-17,560.26%

Profile

Sector
Health Technology
Industry
Biotechnology
Senior VP, Chief Executive &
Medical Officer
Edward M. Kaye
Head-Operations &
Vice President
Gavin T. Malenfant
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs